**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 83711

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Radiation therapy prior to a pancreaticoduodenectomy for adenocarcinoma is associated with longer operative times and higher blood loss**

Aploks K *et al*. Neoadjuvant radiation effect on pancreaticoduodenectomy

Krist Aploks, Minha Kim, Stephanie Stroever, Alexander Ostapenko, Young Bo Sim, Ashwinkumar Sooriyakumar, Arash Rahimi-Ardabily, Ramanathan Seshadri, Xiang Da Dong

**Krist Aploks, Minha Kim, Alexander Ostapenko, Young Bo Sim, Ashwinkumar Sooriyakumar, Arash Rahimi-Ardabily,** Department of General Surgery, Danbury Hospital, Danbury, CT 06810, United States

**Stephanie Stroever,** Department of Research and Innovation, Nuvance Health, Danbury, CT 06810, United States

**Ramanathan Seshadri, Xiang Da Dong,** Division of Surgical Oncology/Hepato-Pancreato-Biliary Surgery, Danbury Hospital, Danbury, CT 06810, United States

**Author contributions:** Aploks K, Kim M, Ostapenko A, Dong XD, and Seshadri R contributed to the conceptualization of the project; Aploks K, Stroever S, Kim M, Ostapenko A, Dong XD, and Seshadri R contributed to the methodology and validation of the data; Stroever S conducted the formal statistical analyses; Aploks K, Kim M, Sim YB, and Sooriyakumar A prepared the original manuscript; Aploks K, Kim M, Ostapenko A, Sim YB, Sooriyakumar A, Rahimi-Ardabily A, Dong XD, and Seshadri R contributed to the final draft revision and editing; Dong XD and Seshadri R supervised the project.

**Corresponding author: Xiang Da Dong, FACS, MD, Chief Doctor,** Division of Surgical Oncology/Hepato-Pancreato-Biliary Surgery, Danbury Hospital, 95 Locust Avenue, Danbury, CT 06810, United States. eric.dong@nuvancehealth.org

**Received:** March 29, 2023

**Revised:** May 12, 2023

**Accepted:** June 12, 2023

**Published online:** August 27, 2023

**Abstract**

BACKGROUND

Pancreatic adenocarcinoma is currently the fourth leading cause of cancer-related deaths in the United States. In patients with “borderline resectable” disease, current National Comprehensive Cancer Center guidelines recommend the use of neoadjuvant chemoradiation prior to a pancreaticoduodenectomy. Although neoadjuvant radiotherapy may improve negative margin resection rate, it is theorized that its administration increases operative times and complexity.

AIM

To investigate the association between neoadjuvant radiotherapy and 30-d morbidity and mortality outcomes among patients receiving a pancreaticoduodenectomy for pancreatic adenocarcinoma.

METHODS

Patients listed in the 2015-2019 National Surgery Quality Improvement Program data set, who received a pancreaticoduodenectomy for pancreatic adenocarcinoma, were divided into two groups based off neoadjuvant radiotherapy status. Multivariable regression was used to determine if there is a significant correlation between neoadjuvant radiotherapy, perioperative blood transfusion status, total operative time, and other perioperative outcomes.

RESULTS

Of the 11458 patients included in the study, 1470 (12.8%) underwent neoadjuvant radiotherapy. Patients who received neoadjuvant radiotherapy were significantly more likely to require a perioperative blood transfusion [adjusted odds ratio (aOR) = 1.58, 95% confidence interval (CI): 1.37-1.82; *P* < 0.001] and have longer surgeries (insulin receptor-related receptor = 1.14, 95%CI: 1.11-1.16; *P* < 0.001), while simultaneously having lower rates of organ space infections (aOR = 0.80, 95%CI: 0.66-0.97; *P* = 0.02) and pancreatic fistula formation (aOR = 0.50, 95%CI: 0.40-0.63; *P* < 0.001) compared to those who underwent surgery alone.

CONCLUSION

Neoadjuvant radiotherapy, while not associated with increased mortality, will impact the complexity of surgical resection in patients with pancreatic adenocarcinoma.

**Key Words:** Pancreaticoduodenectomy; Pancreatic adenocarcinoma; Neoadjuvant chemoradiation; National Surgery Quality Improvement Program; Whipple procedure; Operative time

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Aploks K, Kim M, Stroever S, Ostapenko A, Sim YB, Sooriyakumar A, Rahimi-Ardabily A, Seshadri R, Dong XD. Radiation therapy prior to a pancreaticoduodenectomy for adenocarcinoma is associated with longer operative times and higher blood loss. *World J Gastrointest Surg* 2023; 15(8): 1663-1672

**URL:** [https://www.wjgnet.com/1948-9366/full/v15/i8/1663.htm](https://www.wjgnet.com/1948-9366/full/v15/i8/0000.htm)

**DOI:** https://dx.doi.org/10.4240/wjgs.v15.i8.1663

**Core Tip:** In this retrospective study, we used a national database to investigate the impact that neoadjuvant radiotherapy has on intraoperative and 30-d post-operative outcomes among patients undergoing surgical resection for pancreatic adenocarcinoma. We found that neoadjuvant radiotherapy was associated with longer operative times and the more frequent need for perioperative blood transfusions, but not with increased 30-d mortality. Neoadjuvant radiotherapy was also associated with a lower number of organ space infections and post-operative pancreatic fistula formation. Taken together, the results highlight the challenges that surgeons may face when operating in previously irradiated fields.

**INTRODUCTION**

Pancreatic adenocarcinoma currently represents the fourth leading cause of cancer-related deaths in the United States. In patients suffering from the disease, an R0 resection is the primary and preferred method of treatment[1,2]. While this is often obtainable in patients with early-stage pancreatic malignancies, roughly 85% of patients present with disease that is not amenable to cure with surgical resection alone[3]. The tumors in many of these patients are considered borderline resectable, defined by National Comprehensive Cancer Network (NCCN) guidelines as contact with 180 degrees or less of the superior mesenteric artery or the celiac artery, contact with the common hepatic artery, and/or contact with the superior mesenteric vein/portal vein resulting in contour irregularity or vein thrombosis[4]. According to the NCCN guidelines, such cancers may benefit from treatment with neoadjuvant therapy in the form of chemoradiation[5].

When compared to adjuvant therapy, neoadjuvant chemoradiation has the theoretical benefit of testing for chemosensitivity, increasing the control of micrometastases and circulating tumor cells, ensuring a higher rate of systemic therapy completion, potentially downstaging a disease to make it amenable to surgical therapy and reducing pancreatic leak rates[6–8]. Multiple studies have demonstrated the morbidity benefits that comes with neoadjuvant treatment of patients with borderline resectable pancreatic adenocarcinoma prior to surgery compared with just surgical treatment alone. Among others, these benefits include a decrease in tumor size at the time of surgery, decreased number of positive lymph nodes, fewer organ space infections, and fewer post-operative pancreatic fistulae[9–12].

Despite the purported benefits, neoadjuvant therapy is still regarded with caution and its use remains low in the United States[13]. It is theorized that neoadjuvant therapy increases the rate of gastrointestinal toxicity and impairs post-operative wound healing, which can result in preoperative decompensation and subsequent post-operative morbidities. Neoadjuvant therapy can also theoretically delay definitive surgical resection, which can lead to the development of metastatic disease in non-responders. Radiotherapy, in particular, has been associated with disruption of the pancreatic tissue planes, which is thought to make eventual surgical resection more difficult[14]. Numerous studies have contradicted these ideas, showing that neoadjuvant therapy results in little to no intra- and post-operative increases in morbidity and mortality[9,10,15]. To date, however, many of these prior studies are plagued by single institution analysis with small sample sizes. These samples are even smaller when looking at the number of participants who received neoadjuvant radiotherapy, as chemotherapy remains the lion’s share of neoadjuvant therapy.

The aim of this study was to investigate the effects that neoadjuvant radiation therapy have on both intra-operative and 30-d postoperative morbidities using a nationwide dataset. We specifically hypothesize that among patients receiving a pancreaticoduodenectomy for pancreatic adenocarcinoma, those that also undergo neoadjuvant radiotherapy are more likely to have longer operative times and a perioperative transfusion compared with those who simply receive surgery alone.

**MATERIALS AND METHODS**

***Study design and participants***

We performed a cross sectional study utilizing data from the American College of Surgeons (ACS) National Surgery Quality Improvement Program (NSQIP) database from January 1, 2015 to December 31, 2019. Data from the standard public use file was merged with that from the NSQIP Targeted Pancreatectomy Participant Use Data Files (a separate collection of pancreas-specific variables) using the Case Identification Number (CASEID) variable. Patients older than 18 years old, who had a histological diagnosis of pancreatic adenocarcinoma and underwent a pancreaticoduodenectomy, were included in this study. Patients undergoing resection were identified by one or more of the following additional CPT codes: 48150, 48152, 48153, 48154. This study was exempt from our institutional review board review since the data was de-identified and obtained from a participant use data file.

***Variables***

From the patients included in the study, two groups were formed based on the independent variable of interest: those that received neoadjuvant radiotherapy prior to a pancreaticoduodenectomy, and those that had progressed directly to surgery. For the purposes of this study, neoadjuvant radiotherapy was defined as those receiving treatments within 90 d of the index operation. The primary outcomes of interest were perioperative blood transfusions (defined by the need for a blood transfusion within 72 h of surgery start time; OTHBLEED variable) and total operative time (defined by operative time in minutes; OPTIME variable). The secondary outcomes of interest were 30-d post-operative morbidities and mortality. Specific variables included rate of the following: wound dehiscence, ventilator dependence, stroke, myocardial infarction (MI), deep venous thrombosis (DVT), pulmonary embolism (PE), pneumonia, urinary tract infection, septic shock, superficial surgical site infection (SSI), organ space SSI, 30-d re-operation, 30-d mortality, 30-d readmission, renal failure, hospital length of stay, duration of pancreatic drain, pancreatic fistula, and delayed gastric emptying. Pancreatic fistulae were defined according to the International Study Group for Pancreatic Fistula grading scheme[16].

***Statistical analyses***

StataSE was used for the statistical analyses. Descriptive statistics including mean ± standard deviation for normally distributed continuous variables, median/interquartile range for skewed continuous variables, and number/percentage for categorical variables. We assessed bi-variable differences in outcomes between patients with upfront surgery and neoadjuvant radiotherapy with surgery using the χ2 test, univariable logistic regression, and Fisher’s exact test for categorical variables. Two-tailed Student’s t-tests were used for continuous variables. Variables that were statistically associated (α < 0.05) with both the outcome and the independent variable, as well as those that were predicted theoretical confounders, were included in the multivariate regression analyses. Multivariable negative binomial regression was used for the total operative time variable, and multivariable logistic regression was used for the remaining secondary variables. We used stepwise, backward selection, and tested full/reduced models with the likelihood ratio test to determine the most parsimonious model. For 30-d outcome variables occurring less than 5% of the time, multivariable regression was not performed. For variables missing less than 5% of data, the listwise deletion method was used. Variables missing greater than 5% of data were reported as “unknown” in the tables.

**RESULTS**

Query of the ACS-NSQIP database identified a total of 11775 patients who underwent surgery for pancreatic adenocarcinoma from 2015 to 2019. Patients who had data missing with regards to neoadjuvant radiation therapy status, and patients in whom SSIs were reported upon admission, were excluded from the analyses. This left a final cohort of 11458 patients. The cohort was then split into two study groups based off neoadjuvant radiotherapy exposure: 1470 patients (12.8%) received neoadjuvant radiation therapy, compared with 9988 (87.2%) patients who proceeded directly to surgery (Figure 1).

Patients undergoing neoadjuvant radiotherapy were more likely to be younger, female, non-Hispanic white, diabetic, and of normal body weight (all *P* < 0.04). Conversely, patients undergoing surgery without radiotherapy were more likely to be Hispanic, overweight/obese, and jaundiced (all *P* < 0.002). They were also more likely to have chronic obstructive pulmonary disease, dyspnea, and hypertension (all *P* < 0.05) (Table 1).

With regard to tumor characteristics and operative approaches, patients receiving neoadjuvant radiotherapy were more likely to have a lower T-stage, lower N-stage, receive an elective surgery, have a higher wound class, and have a smaller pancreatic duct size (all *P* < 0.04). Such patients were also more likely to undergo an open surgical approach that involved resection of an artery or vein (all *P* < 0.001) (Table 2).

Within the first 30 d following surgery, bi-variable statistical analyses revealed that patients receiving surgical treatment only were more likely to experience an MI, PE, pneumonia, organ space infection, delayed gastric emptying, and pancreatic fistula (all *P* < 0.035). Such patients also had a higher 30-d mortality rate, longer hospital stay, a drain that remained in place after 30 d, and a longer total operative time (all *P* < 0.041). Patients undergoing neoadjuvant radiation were more likely to receive a DVT and receive a perioperative transfusion (all *P* < 0.024). On multivariate analyses of the 30-d outcomes that occurred at a rate of greater than 5% in both study groups, neoadjuvant radiotherapy was associated with longer total operative times and the need for a perioperative transfusion. Patients undergoing neoadjuvant radiotherapy, however, were statistically less likely to acquire an organ space infection or a pancreatic fistula compared with patients who underwent surgery alone (Tables 3 and 4). While total hospital stay, presence of drain on post-operative day 30, and delayed gastric emptying occurred at significantly lower rates in the neoadjuvant therapy group upon univariate statistical analyses, this difference was not statistically significant on multivariable analyses.

**DISCUSSION**

In the past, numerous studies have implicated single and multi-agent neoadjuvant chemotherapy with both tumor downstaging and an increased rate of R0 resections[17,18]. In comparison with neoadjuvant chemotherapy, however, evidence demonstrating similar advantages with neoadjuvant radiation therapy have been somewhat sparce. In 2019, Jiang *et al*[19] used the NCDB database to show an increased R0 resection and overall survival rate among patients who utilized neoadjuvant stereotactic body radiation therapy in addition to neoadjuvant chemotherapy compared to just neoadjuvant chemotherapy alone[19]. A paper by Chung *et al*[20] showed that higher doses of radiation (*i.e.* intensity-modulate radiation therapy) corresponded to increased 1 year survival and progression-free survival with no significant increase in short or long-term side effects[20]. Upon initial analyses of our study data, we found that patients undergoing neoadjuvant radiotherapy prior to surgery had smaller tumors and less positive lymph nodes on pathologic staging compared with those undergoing surgery alone. This suggests that neoadjuvant therapy successfully worked to downstage the tumors prior to surgical re-section. Although this effect could be confounded by the substantial difference in baseline demographic data between the two study groups, these results are nearly identical to those found in similarly designed NSQIP studies comparing neoadjuvant chemoradiation to surgery alone[9].

When examining our two primary outcome variables, we found a statistically significant increase in total operative time and perioperative transfusion requirements among patients receiving neoadjuvant radiation therapy compared to just surgery alone. This is the first time that such associations have been reported using multivariable analyses with patients receiving only neoadjuvant radiotherapy (*vs* neoadjuvant radiotherapy and/or chemotherapy). An analysis of 2005-2010 NSQIP data from Cho *et al*[14] found similar results, but with bi-variable analysis only[14]. Similarly, a study using NSQIP data from 2014 to 2015 showed that the perioperative transfusion requirement rate among patients receiving neoadjuvant therapy (chemotherapy and/or radiotherapy) was significantly higher than the rate in patients who progressed directly to surgery[21]. In 2021, Krell *et al*[22] showed that (with propensity score matching) there were increased total operative times and more frequent perioperative blood transfusions among those receiving neoadjuvant therapy (chemotherapy and/or radiotherapy) prior to surgery compared to those undergoing surgery alone[22].

Previously, it has been suggested that these differences in perioperative blood transfusions and total operative time are secondary to an increase in the number of borderline resectable cancers in the neoadjuvant therapy groups[14]. By definition, these tumors involve major blood vessels and usually require more complex dissections when compared to lower stage tumors. While the increased number of vascular resections within our neoadjuvant therapy group supports this conclusion, an alternative explanation may be that neoadjuvant radiotherapy itself impacts the complexity of the eventual surgical resection. Histologic evaluation of pancreatic tumors before and after neoadjuvant chemoradiation has shown a significant increase in the ratio of fibrosis to neoplastic cells, indicating a change in the tissue character following neoadjuvant therapy[23]. While such fibrosis has been theorized to be protective against post-operative complications like pancreatic fistulae formation, its distortional effect on classic tissue planes may make the surgery itself more difficult[24]. It is important for the operating surgeon to keep this in mind, as it may impact both the procedure type (*i.e.* open *vs* minimally invasive) and the expected post-operative complications.

Overall, the 30-d post-operative complication and morbidity rates were similar between both study groups. Of the variables that were analyzed using multivariable regression, only organ space infections and pancreatic fistula rates were significantly different between the two study groups. Numerous studies have detailed the decreased rate of both variables in patients receiving neoadjuvant therapy, suggesting that neoadjuvant radiotherapy may have a small positive effect on short term post-operative morbidity[9,10,14,21,25].

Although the data provided in this study lend credence to the safety and efficacy of neoadjuvant radiotherapy, there are some limitations to keep in mind. Data regarding the specific details of neoadjuvant radiotherapy regimen used (duration, intensity, timing, prior to surgery) is not available within the NSQIP database, making it impossible to account for related confounding factors in our data analyses. Additionally, NSQIP only collects data on post-operative outcomes that occur within 30 d of the index operation, making the results of this study difficult to extrapolate over a longer-termed period. Facility and surgeon data are also not reported in NSQIP, which again may represent confounding factors that our analyses did not consider. Finally, it is impossible to determine whether a patient’s tumor is resectable or borderline resectable (per NCCN guidelines) based on the information reported in NSQIP. As surgeries may be more difficult in borderline resectable patients, this represents a further confounding factor that could not be completely controlled for.

**CONCLUSION**

The results of this study contribute to the notion that neoadjuvant radiotherapy is both safe and effective to use prior to a pancreaticoduodenectomy for pancreatic adenocarcinoma. The study does, however, suggest that adverse intraoperative outcomes like total operative time and perioperative transfusion requirements may be increased among patients receiving surgery for cancer resection after neoadjuvant radiotherapy. Surgeons are encouraged to keep in mind the potential positive and negative effects that neoadjuvant radiotherapy has on the complexity of the eventual surgery when it is performed.

**ARTICLE HIGHLIGHTS**

***Research background***

Pancreatic adenocarcinoma is currently the fourth leading cause of cancer-related deaths in the United States. In addition to neoadjuvant chemotherapy, neoadjuvant radiotherapy may improve negative margin resection rates. This study seeks to investigate the safety and efficacy of neoadjuvant radiotherapy in patients with pancreatic adenocarcinoma.

***Research motivation***

By better clarifying the benefits and drawbacks that are associated with neoadjuvant radiotherapy administration in patients with pancreatic adenocarcinoma, practitioners can make informed decisions regarding its use.

***Research objectives***

The primary objective of the study was to investigate the effect that neoadjuvant radiotherapy has on both intra-operative and 30-d postoperative morbidities in patients with pancreatic adenocarcinoma.

***Research methods***

Using 2015-2019 data from the National Surgery Quality Improvement Program data set, we divided pancreatic adenocarcinoma patients into two groups based on neoadjuvant radiotherapy status. Then we performed univariable and multivariable analyses to identify differences in baseline characteristics and outcomes between the two groups.

***Research results***

When compared to patients with pancreatic adenocarcinoma who underwent surgical resection alone, patients who underwent neoadjuvant radiotherapy were more likely to have longer surgeries and higher perioperative blood loss. The neoadjuvant radiotherapy patients were also less likely to have organ space infections and pancreatic fistulae formation.

***Research conclusions***

Neoadjuvant radiotherapy has significant effects on intraoperative and 30-d postoperative morbidity in patients with pancreatic adenocarcinoma. It may make eventual surgical resection of the cancer more complex.

***Research perspectives***

Future research should focus on finding new methods that work to minimize the negative side effects associated with neoadjuvant radiotherapy in patients with pancreatic adenocarcinoma.

**REFERENCES**

1 **Vincent A**, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. *Lancet* 2011; **378**: 607-620 [PMID: 21620466 DOI: 10.1016/S0140-6736(10)62307-0]

2 **Ryan DP**, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. *N Engl J Med* 2014; **371**: 1039-1049 [PMID: 25207767 DOI: 10.1056/NEJMra1404198]

3 **Konstantinidis IT**, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF, Deshpande V, Hong TS, Kwak EL, Lauwers GY, Ryan DP, Wargo JA, Lillemoe KD, Ferrone CR. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections *versus* locally advanced unresectable tumors? What is a "true" R0 resection? *Ann Surg* 2013; **257**: 731-736 [PMID: 22968073 DOI: 10.1097/SLA.0b013e318263da2f]

4 **Isaji S**, Mizuno S, Windsor JA, Bassi C, Fernández-Del Castillo C, Hackert T, Hayasaki A, Katz MHG, Kim SW, Kishiwada M, Kitagawa H, Michalski CW, Wolfgang CL. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. *Pancreatology* 2018; **18**: 2-11 [PMID: 29191513 DOI: 10.1016/j.pan.2017.11.011]

5 **National Comprehensive Cancer Network.** Pancreatic Adenocarcinoma (Version 2.2021). [cited 10 January 2022]. Available from: https://www.nccn.org/professionals/physician\_gls/pdf/pancreatic.pdf

6 **Lambert A**, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. *Ther Adv Med Oncol* 2019; **11**: 1758835919875568 [PMID: 31598142 DOI: 10.1177/1758835919875568]

7 **Russo S**, Ammori J, Eads J, Dorth J. The role of neoadjuvant therapy in pancreatic cancer: a review. *Future Oncol* 2016; **12**: 669-685 [PMID: 26880384 DOI: 10.2217/fon.15.335]

8 **Kang CM**, Chung YE, Park JY, Sung JS, Hwang HK, Choi HJ, Kim H, Song SY, Lee WJ. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. *J Gastrointest Surg* 2012; **16**: 509-517 [PMID: 22183861 DOI: 10.1007/s11605-011-1784-3]

9 **Cools KS**, Sanoff HK, Kim HJ, Yeh JJ, Stitzenberg KB. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy. *J Surg Oncol* 2018; **118**: 455-462 [PMID: 30114330 DOI: 10.1002/jso.25183]

10 **Cooper AB**, Parmar AD, Riall TS, Hall BL, Katz MH, Aloia TA, Pitt HA. Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates? *J Gastrointest Surg* 2015; **19**: 80-6; discussion 86-7 [PMID: 25091851 DOI: 10.1007/s11605-014-2620-3]

11 **Ferrone CR**, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. *Ann Surg* 2015; **261**: 12-17 [PMID: 25599322 DOI: 10.1097/SLA.0000000000000867]

12 **Lof S**, Korrel M, van Hilst J, Alseidi A, Balzano G, Boggi U, Butturini G, Casadei R, Dokmak S, Edwin B, Falconi M, Keck T, Malleo G, de Pastena M, Tomazic A, Wilmink H, Zerbi A, Besselink MG, Abu Hilal M; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS). Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study. *Ann Surg Oncol* 2020; **27**: 1986-1996 [PMID: 31848815 DOI: 10.1245/s10434-019-08137-6]

13 **Cloyd JM**, Tsung A, Hays J, Wills CE, Bridges JF. Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research. *World J Gastroenterol* 2020; **26**: 375-382 [PMID: 32063686 DOI: 10.3748/wjg.v26.i4.375]

14 **Cho SW**, Tzeng CW, Johnston WC, Cassera MA, Newell PH, Hammill CW, Wolf RF, Aloia TA, Hansen PD. Neoadjuvant radiation therapy and its impact on complications after pancreaticoduodenectomy for pancreatic cancer: analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). *HPB (Oxford)* 2014; **16**: 350-356 [PMID: 24112766 DOI: 10.1111/hpb.12141]

15 **Laurence JM**, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. *J Gastrointest Surg* 2011; **15**: 2059-2069 [PMID: 21913045 DOI: 10.1007/s11605-011-1659-7]

16 **Bassi C**, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink MG, Conlon K, Del Chiaro M, Falconi M, Fernandez-Cruz L, Fernandez-Del Castillo C, Fingerhut A, Friess H, Gouma DJ, Hackert T, Izbicki J, Lillemoe KD, Neoptolemos JP, Olah A, Schulick R, Shrikhande SV, Takada T, Takaori K, Traverso W, Vollmer CR, Wolfgang CL, Yeo CJ, Salvia R, Buchler M; International Study Group on Pancreatic Surgery (ISGPS). The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. *Surgery* 2017; **161**: 584-591 [PMID: 28040257 DOI: 10.1016/j.surg.2016.11.014]

17 **Hackert T**, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C, Strobel O, Jäger D, Ulrich A, Büchler MW. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. *Ann Surg* 2016; **264**: 457-463 [PMID: 27355262 DOI: 10.1097/SLA.0000000000001850]

18 **Mokdad AA**, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, Yopp AC, Mansour JC, Choti MA, Polanco PM. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. *J Clin Oncol* 2017; **35**: 515-522 [PMID: 27621388 DOI: 10.1200/JCO.2016.68.5081]

19 **Jiang W**, Haque W, Verma V, Butler EB, Teh BS. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma. *Acta Oncol* 2019; **58**: 1259-1266 [PMID: 31237185 DOI: 10.1080/0284186X.2019.1631472]

20 **Chung SY**, Chang JS, Lee BM, Kim KH, Lee KJ, Seong J. Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. *Radiother Oncol* 2017; **123**: 438-445 [PMID: 28464997 DOI: 10.1016/j.radonc.2017.04.010]

21 **Czosnyka NM**, Borgert AJ, Smith TJ. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review. *HPB (Oxford)* 2017; **19**: 927-932 [PMID: 28747265 DOI: 10.1016/j.hpb.2017.07.001]

22 **Krell RW**, McNeil LR, Yanala UR, Are C, Reames BN. Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Propensity-Matched Analysis of Postoperative Complications Using ACS-NSQIP. *Ann Surg Oncol* 2021; **28**: 3810-3822 [PMID: 33386542 DOI: 10.1245/s10434-020-09460-z]

23 **Sasson AR**, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF, Eisenberg BL. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. *Int J Gastrointest Cancer* 2003; **34**: 121-128 [PMID: 15361645 DOI: 10.1385/IJGC:34:2-3:121]

24 **Ishikawa O**, Ohigashi H, Imaoka S, Teshima T, Inoue T, Sasaki Y, Iwanaga T, Nakaizumi A. Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreatoduodenectomy. *Arch Surg* 1991; **126**: 885-889 [PMID: 1854249 DOI: 10.1001/archsurg.1991.01410310095014]

25 **Hank T**, Sandini M, Ferrone CR, Rodrigues C, Weniger M, Qadan M, Warshaw AL, Lillemoe KD, Fernández-Del Castillo C. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy. *JAMA Surg* 2019; **154**: 943-951 [PMID: 31411659 DOI: 10.1001/jamasurg.2019.2272]

**Footnotes**

**Institutional review board statement:** Ethical review and approval were waived for this study since the data used was de-identified and obtained from a participant use data file.

**Informed consent statement:** This study was a retrospective review that utilized only de-identified patient data from National Cancer Database. Given this fact, no signed informed consent is needed.

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Data sharing statement:** Data was obtained with permission from the American College of Surgeon's National Cancer Database. NSQIP data can be obtained by visiting https://www.facs.org/quality-programs/data-and-registries/acs-nsqip/.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** March 29, 2023

**First decision:** April 26, 2023

**Article in press:** June 12, 2023

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Tan CL, China; Yi SQ, Japan **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:** Fan JR

**Figure Legends**



**Figure 1 CONSORT diagram of study cohort.** ACS-NSQIP: American College of Surgeons-National Surgery Quality Improvement Program.

**Table 1 Demographics and preoperative characteristics of patients with adenocarcinoma of the pancreas undergoing a pancreaticoduodenectomy from 2015 to 2019, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Subcategory** | **Initial surgery** | **Neoadjuvant radiation** | ***P* value** |
| ***n* = 9988** | ***n* = 1470** |
| Age in yr | Less than 50 | 511 (5.1) | 89 (6.1) |  |
|  | 50-59 | 1638 (16.4) | 304 (20.7) |  |
|  | 60-69 | 3526 (35.3) | 585 (39.8) | < 0.001a |
|  | 70-79 | 3287 (32.9) | 430 (29.3) |  |
|  | 80 and above | 1026 (10.3) | 62 (4.2) |  |
| Male |  | 5340 (53.5) | 743 (50.5) | 0.036a |
| Race | White | 7392 (81.6) | 1203 (84.3) |  |
|  | Black/African American | 748 (8.3) | 127 (8.9) |  |
|  | Hispanic | 462 (5.1) | 54 (3.8) | < 0.001a |
|  | Asian | 427 (4.7) | 38 (2.7) |  |
|  | Other | 33 (0.4) | 5 (0.4) |  |
|  | Not reported | 926 | 43 |  |
| BMI | Normal | 3683 (36.9) | 618 (42.0) |  |
|  | Underweight | 244 (2.4) | 37 (2.5) |  |
|  | Overweight | 3591 (36) | 505 (34.4) | 0.002a |
|  | Obese | 1614 (16.2) | 203 (13.8) |  |
|  | Morbidly obese | 856 (8.6) | 107 (7.3) |  |
| Diabetes |  | 2859 (28.6) | 461 (31.4) | 0.031a |
| Smoking |  | 1650 (16.5) | 238 (16.2) | 0.751 |
| COPD |  | 394 (3.9) | 42 (2.9) | 0.042a |
| Dyspnea |  | 507 (5.1) | 57 (3.9) | 0.047a |
| HTN |  | 5418 (54.2) | 693 (47.1) | < 0.001a |
| Preoperative steroid use |  | 239 (2.4) | 42 (2.9) | 0.283 |
| Jaundice |  | 5759 (58.0) | 431 (29.7) | < 0.001a |
| Biliary stent |  | 6457 (64.7) | 979 (66.6) | 0.235 |
| Albumin, mean ± SD |  | 3.69 (0.60) | 3.85 (0.50) | < 0.001a |

a*P* < 0.05.

BMI: Body mass index; COPD: Chronic obstructive pulmonary disease; HTN: Hypertension; SD: Standard deviation.

**Table 2 Operative characteristics of patients with adenocarcinoma of the pancreas undergoing a pancreaticoduodenectomy from 2015 to 2019, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Subcategory** | **Initial surgery** | **Neoadjuvant radiation** | ***P* value** |
| ***n* = 9988** | ***n* = 1470** |
| Elective surgery |  | 8921 (89.4) | 1423 (96.8) | < 0.001a |
| T-stage | T0/T1 | 2969 (29.7) | 867 (59.0) |  |
|  | T2 | 6133 (61.4) | 544 (37.0) | < 0.001a |
|  | T3/T4 | 666 (6.7) | 32 (2.2) |  |
|  | Tis/unknown | 128 (1.3) | 39 (2.7) |  |
| N-stage | N0 | 2969 (29.7) | 867 (59.0) |  |
|  | N1 | 6133 (61.4) | 544 (37.0) | < 0.001a |
|  | N2 | 666 (6.7) | 32 (2.18) |  |
| M-stage | M0 | 7260 (72.7) | 1109 (75.4) |  |
|  | M1 | 172 (1.7) | 20 (1.4) | 0.073 |
|  | Unknown | 2556 (25.6) | 341 (23.2) |  |
| Wound class | Clean | 242 (2.4) | 33 (2.2) |  |
|  | Clean-contaminated | 7915 (79.3) | 1142 (77.7) | 0.034a |
|  | Contaminated | 1547 (15.5) | 233 (15.9) |  |
|  | Dirty | 284 (2.8) | 62 (4.2) |  |
| Pancreatic duct size | < 3 mm | 1987 (24.9) | 304 (26.3) |  |
|  | 3-6 mm | 4527 (56.8) | 685 (59.2) |  |
|  | > 6 mm | 1461 (18.3) | 168 (14.5) | 0.007a |
|  | Unknown | 2013 | 315 |  |
| Resection of artery or vein |  | 2217 (22.4) | 554 (37.9) | < 0.001a |
| Surgery approach | Open | 9112 (91.2) | 1386 (94.4) | < 0.001a |
|  | Robotic/laparoscopic | 875 (8.8) | 83 (5.7) |  |

a*P* < 0.05.

**Table 3 Thirty-day postoperative complications for patients with adenocarcinoma of the pancreas undergoing a pancreaticoduodenectomy from 2015 to 2019, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Complication** | **Initial surgery** | **Neoadjuvant radiation** | ***P* value** |
| ***n* = 9988** | ***n* = 1470** |
| Wound dehiscence | 110 (1.1) | 16 (1.1) | 0.965 |
| Ventilator dependent > 48 h | 223 (2.2) | 38 (2.6) | 0.398 |
| Stroke | 29 (0.3) | 3 (0.2) | 0.791 |
| Myocardial infarction | 124 (1.2) | 9 (0.6) | 0.035a |
| DVT | 269 (2.7) | 55 (3.7) | 0.024a |
| Pulmonary embolism | 108 (1.1) | 5 (0.3) | 0.004a |
| Pneumonia | 305 (3.1) | 30 (2.0) | 0.031a |
| UTI | 247 (2.5) | 32 (2.2) | 0.491 |
| Septic shock | 207 (2.1) | 34 (2.3) | 0.545 |

a*P* < 0.05.

DVT: Deep venous thrombosis; UTI: Urinary tract infection.

**Table 4 Odds ratios for 30-day postoperative complications for patients with adenocarcinoma of the pancreas undergoing a pancreaticoduodenectomy from 2015 to 2019**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Complication** | **Neoadjuvant radiotherapy crude OR (95%CI)** | **Crude *P* value** | **Neoadjuvant radiotherapy adjusted OR/IRR (95%CI)** | **Adjusted *P* value** |
| Total operative time  | 0.15 (0.13, 0.16) | < 0.001a | 1.14 (1.11,1.16)1 | < 0.001a |
| Perioperative transfusion | 1.49 (1.32, 1.69) | < 0.001a | 1.58 (1.37, 1.82)2 | < 0.001a |
| Superficial SSI | 1.13 (0.93, 1.38) | 0.217 | NP | NP |
| Organ space SSI | 0.76 (0.63, 0.91) | 0.004a | 0.80 (0.66, 0.97)3 | 0.020a |
| 30-d reoperation | 1.03 (0.80, 1.32) | 0.832 | NP | NP |
| 30-d mortality rate | 0.40 (0.21, 0.75) | 0.005a | NP | NP |
| 30-d readmission rate | 1.14 (0.98, 1.32) | 0.090 | NP | NP |
| Renal failure | 0.74 (0.37, 1.47) | 0.382 | NP | NP |
| Total hospital stay | 0.09 (0.06, 0.12) | < 0.001a | 0.99 (0.96, 1.02)4 | 0.640 |
| Drain in place on POD 30 | 0.76 (0.61, 0.99) | 0.041a | 0.82 (0.64, 1.06)5 | 0.124 |
| Pancreatic fistula | 0.47 (0.38, 0.58) | < 0.001a | 0.50 (0.40, 0.63)5 | < 0.001a |
| Delayed gastric emptying | 0.81 (0.69, 0.95) | 0.010a | 0.86 (0.72, 1.01)5 | 0.073 |

a*P* < 0.05.

1Odds ratio was adjusted for: Albumin, age, sex, race, body mass index (BMI), diabetes, dyspnea, chronic obstructive pulmonary disease (COPD), hypertension, elective surgery, wound class, biliary stent, pancreatic duct size, perioperative transfusion requirement, surgical approach, resection of artery or vein.

2Odds ratio was adjusted for: Albumin, age, sex, race, BMI, diabetes, dyspnea, COPD, hypertension, elective surgery, wound class, biliary stent, surgical approach, resection of artery or vein, T-stage, N-stage.

3Odds ratio was adjusted for: Age, race, BMI, diabetes, steroids, wound class, American society of anesthesiologists (ASA) class, surgical approach, resection of artery or vein.

4Odds ratio was adjusted for: Age, race, BMI, diabetes, steroids, wound class, ASA class, surgical approach, resection of artery or vein, organ space infection, failure to wean off ventilator by post-operative day (POD) 30, drain in place by POD 30, return to the odds ratio within 30 d of index operation, delayed gastric emptying, T-stage, N-stage, M-stage.

5Odds ratio was adjusted for: Age, race, BMI, diabetes, steroids, wound class, ASA class, surgical approach, resection of artery or vein.

IRR: Insulin receptor-related receptor; NP: Not performed; OR: Odds ratio; POD: Post-operative day; SSI: Surgical site infection.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**